Home › NDC Lookup › RxCUI directory › RxCUI 603203

Erlotinib 100 MG Oral Tablet — RxCUI 603203

RxNorm drug concept · Semantic clinical drug
RxCUI 603203 Semantic clinical drug · SCD ● Current RxNorm concept 28 FDA products 52 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI603203
Official nameErlotinib 100 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known aserlotinib 100 MG (equivalent to erlotinib HCl 109.3 MG) Oral Tablet
FDA products mapped28
Package NDCs mapped52
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Erlotinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Erlotinib works by blocking a specific protein — EGFR — that drives tumor growth. But it's most effective when your tumor has one of two particular gene changes: an exon 19 deletio...
  • Why does my doctor want me tested for an EGFR mutation before starting erlotinib?
  • Yes — this one really matters. You should always take erlotinib on an empty stomach, at least 1 hour before eating or 2 hours after a meal. Food can nearly double the amount of erl...
  • Does it matter if I eat before taking erlotinib?
📖 Read our full Erlotinib guide →

🕸️ Concept Web — How Erlotinib 100 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Erlotinib 100 MG Oral Tablet RxCUI 603203

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Erlotinib 337525
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Tarceva 337526
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Erlotinib Oral Tablet 477321
    • Erlotinib Oral Product 1162503
    • Erlotinib Pill 1162504
    • Erlotinib Oral Tablet [Tarceva] 540423
    • Tarceva Oral Product 1179040
    • Tarceva Pill 1179041
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Erlotinib 100 MG 603202
    • Erlotinib 100 MG Oral Tablet [Tarceva] 1088251
    • Erlotinib 100 MG [Tarceva] 1088250

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Erlotinib 100 MG SCDC · 603202
  • Erlotinib Oral Tablet SCDF · 477321
  • Erlotinib Oral Product SCDG · 1162503
  • Erlotinib Pill SCDG · 1162504

Brand-Name Concepts

  • Erlotinib 100 MG Oral Tablet [Tarceva] SBD · 1088251
  • Erlotinib 100 MG [Tarceva] SBDC · 1088250
  • Erlotinib Oral Tablet [Tarceva] SBDF · 540423
  • Tarceva Oral Product SBDG · 1179040
  • Tarceva Pill SBDG · 1179041
  • Tarceva BN · 337526

📦 FDA Products & Package NDCs

28 products · 52 package NDCs
52 package NDCs map to RxCUI 603203 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
72205-0082-30 1 BOTTLE in 1 CARTON (72205-082-30) / 30 TABLET, FILM COATE... Erlotinib Hydrochloride Novadoz Pharmaceuticals LLC 2021-05-11
72485-0218-30 1 BOTTLE in 1 BOX (72485-218-30) / 30 TABLET, FILM COATED i... Erlotinib Armas Pharmaceuticals Inc. 2019-11-06
Observed labelers: Zydus Lifesciences Limited (9) · Zydus Pharmaceuticals USA Inc. (9) · Alembic Pharmaceuticals Inc. (6) · Alembic Pharmaceuticals Limited (6) · Aurobindo Pharma Limited (6) · Sun Pharmaceutical Industries, Inc. (6) · +4 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.